New treatment to reduce bleeding in patients with low platelet counts
SynthoPlate: Intravenous Hemostatic Nanotechnology to Mitigate Bleeding in Thrombocytopenia
This study is testing a new type of treatment that uses tiny particles to help people with low platelet counts, like those undergoing chemotherapy or dealing with autoimmune disorders, by providing a better way to prevent excessive bleeding.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Haima Therapeutics, LLC NIH-funded |
| Lab location | 1 site (Cleveland, United States) |
| Project ID | NIH-11285688 on NIH RePORTER |
What this research studies
This research focuses on developing a novel intravenous nanotechnology designed to help patients with thrombocytopenia, a condition characterized by low platelet counts that can lead to excessive bleeding. The approach aims to create a synthetic platelet substitute that can effectively mitigate bleeding risks, especially in patients undergoing chemotherapy or suffering from autoimmune disorders. By addressing the limitations of current platelet transfusions, this research seeks to provide a more reliable and longer-lasting solution for managing bleeding complications in these patients.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with thrombocytopenia, particularly those with autoimmune conditions or those undergoing chemotherapy.
Not a fit: Patients with normal platelet counts or those whose bleeding issues are not related to thrombocytopenia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of bleeding complications for patients with low platelet counts, improving their quality of life and treatment outcomes.
How similar studies have performed: While the approach of using nanotechnology for hemostatic purposes is innovative, similar strategies have shown promise in other areas of bleeding management, indicating potential for success.
Where this research is happening
Cleveland, United States
- Haima Therapeutics, LLC — Cleveland, United States (Active)
Researchers
- Principal investigator: Bruckman, Michael Arthur — Haima Therapeutics, LLC
- Study coordinator: Bruckman, Michael Arthur
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.